Kennedy Capital Management, Inc. Black Diamond Therapeutics, Inc. Transaction History
Kennedy Capital Management, Inc.
- $4.23 Billion
- Q4 2024
A detailed history of Kennedy Capital Management, Inc. transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Kennedy Capital Management, Inc. holds 433,793 shares of BDTX stock, worth $989,048. This represents 0.02% of its overall portfolio holdings.
Number of Shares
433,793
Previous 657,036
33.98%
Holding current value
$989,048
Previous $2.86 Million
67.53%
% of portfolio
0.02%
Previous 0.07%
Shares
7 transactions
Others Institutions Holding BDTX
# of Institutions
94Shares Held
47.6MCall Options Held
2.9KPut Options Held
69.4K-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.5MShares$23.9 Million0.01% of portfolio
-
Bellevue Group Ag Kuesnacht, V88.52MShares$19.4 Million0.36% of portfolio
-
Vestal Point Capital, LP New York, NY5.6MShares$12.8 Million0.71% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$10.1 Million0.68% of portfolio
-
Black Rock Inc. New York, NY3.22MShares$7.34 Million0.0% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $82.9M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...